Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.

The Journal of biological chemistry - 18 Jul 2008

Tur Vicente, van der Sloot Almer M, Reis Carlos R, Szegezdi Eva, Cool Robbert H, Samali Afshin, Serrano Luis, Quax Wim J

Abstract excerpt

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anticancer agent that selectively induces apoptosis in a variety of cancer cells by interacting with death receptors DR4 and DR5. TRAIL can also bind to decoy receptors (DcR1, DcR2, and osteoprotegerin receptor) that cannot induce apoptosis. Different tumor types respond either to DR4 or to DR5 activation, and chemotherapeutic drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Protein Structure, Tertiary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Recombinant Proteins

Share to Static Electricity

Share to Surface Plasmon Resonance

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Tumor Necrosis Factors

Source

Identifiers

PMID: 18474604
DOI: 10.1074/jbc.M800457200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.PMID 18474604Read ↗

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Semantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.Semantic proximity Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

Directed Change in TNFα Specificity to Create DR5 Antagonists.Semantic proximity Read ↗

Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.Semantic proximity Read ↗

Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects.Semantic proximity Read ↗

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity.Semantic proximity Read ↗

TRAIL as a target in anti-cancer therapy.Semantic proximity Read ↗

Therapeutic applications of TRAIL receptor agonists in cancer and beyondSemantic proximity Read ↗

The TRAIL apoptotic pathway in cancer onset, progression and therapy.Semantic proximity Read ↗

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.